ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
217.14
-4.88 (-2.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed
ResMed Revenue
ResMed had revenue of $1.42B in the quarter ending December 31, 2025, with 10.98% growth. This brings the company's revenue in the last twelve months to $5.40B, up 9.57% year-over-year. In the fiscal year ending June 30, 2025, ResMed had annual revenue of $5.15B with 9.84% growth.
Revenue (ttm)
$5.40B
Revenue Growth
+9.57%
P/S Ratio
5.83
Revenue / Employee
$540,894
Employees
9,980
Market Cap
31.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medline | 28.43B |
| Becton, Dickinson and Company | 21.92B |
| Baxter International | 11.24B |
| Alcon | 10.40B |
| Solventum | 8.33B |
| The Cooper Companies | 4.15B |
| Align Technology | 4.03B |
| AptarGroup | 3.78B |
RMD News
- 27 days ago - Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 - GlobeNewsWire
- 2 months ago - Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach - GlobeNewsWire
- 2 months ago - ResMed At $250: Missed Opportunity Or A Trap In The Making? - Forbes
- 2 months ago - Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana - GlobeNewsWire
- 3 months ago - Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge - Reuters
- 3 months ago - Analysts Maintain Bull Case On ResMed Despite Competition Concerns - Benzinga
- 3 months ago - ResMed beats quarterly profit estimates on strong demand for its sleep devices - Reuters
- 3 months ago - ResMed Earnings Call Transcript: Q2 2026 - Transcripts